Terms: = Ovarian cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Diagnosis
8 results:
1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
2. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract] [Full Text] [Related]
3. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract] [Full Text] [Related]
4. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
[TBL] [Abstract] [Full Text] [Related]
5. Fallopian Tube Lesions in Women at High Risk for ovarian cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract] [Full Text] [Related]
6. [The morphological and immunohistochemical characteristics of changes in the fallopian tube mucosa in ovarian epithelial tumors].
Asaturova AV; Ezhova LS; Faizullina NM; Sannikova MV; Khabas GN
Arkh Patol; 2016; 78(2):3-9. PubMed ID: 27070769
[TBL] [Abstract] [Full Text] [Related]
7. Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer.
Wang J; Sharma A; Ghamande SA; Bush S; Ferris D; Zhi W; He M; Wang M; Wang X; Miller E; Hopkins D; Macfee M; Guan R; Tang J; She JX
PLoS One; 2013; 8(11):e78393. PubMed ID: 24244307
[TBL] [Abstract] [Full Text] [Related]
8. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract] [Full Text] [Related]
